In Brief: Cooper Companies
This article was originally published in The Gray Sheet
Cooper Companies: Firm's board of directors names Thomas Bender to president and CEO, filling a position that has been vacant since 1990 when Arthur Bass stepped down. Bender has held the position of chief operating officer for Cooper since August 1994, and has also served since June 1991 as president and CEO of CooperVision, Cooper Companies' contact lens business. He will remain in his current positions in addition to serving as president and CEO...
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.